The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.
Eli Lilly's experimental weight loss drug, retatrutide, has demonstrated encouraging results in helping obese adults lose weight.
This could reduce the cost of Zepbound to $168 per month. Many health insurance plans don't cover the weight loss drug Zepbound because it's so new. It was approved by the FDA at the end of 2023 ...
Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...
A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like ...
The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...
A taurine-derived metabolite may hold the key to regulating food intake and body weight, potentially inspiring a new class of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback